Proscia Expands Digital Pathology Platform with FDA Clearance for Interoperability — Proscia Inc.

Event summary

Proscia received FDA 510(k) clearance for Concentriq AP-Dx, including compatibility with Leica Aperio GT 450 DX slide scanner and cloud deployment.
The clearance includes a Predetermined Change Control Plan (PCCP), allowing Proscia to expand interoperability without further 510(k) submissions.
Concentriq AP-Dx is used by laboratories managing 12 million patient cases annually, including 16 of the top 20 pharmaceutical companies.

The big picture

Proscia's FDA clearance for Concentriq AP-Dx with a PCCP addresses the growing demand for flexible, interoperable digital pathology solutions. As laboratories struggle with a declining pathologist workforce and increasing diagnostic demands, Proscia positions itself as a key player in enabling scalable, cloud-based pathology services. The company's top KLAS Research scores further validate its market leadership.

What we're watching

Interoperability Expansion: How Proscia will leverage the PCCP to integrate additional FDA-cleared scanners and technologies.
Market Adoption: Whether Concentriq AP-Dx can sustain its growth among diagnostic laboratories and pharmaceutical companies.
Regulatory Dynamics: The pace at which Proscia can navigate regulatory hurdles to maintain its competitive edge in digital pathology.